The most prevalent gene fusion is the TMPRSS2-ERG, present in nearly half of all human prostate cancers, followed by rearrangements involving the ETV1, ETV4, ETV5 and FLI1 genes, often with promoter fusion partners other than TMPRSS2 [3–10]. Here, ERG is linked to prostate carcinoma.